Skip to content
lifestyle.cosmeticsurgeryinsider.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Entrada Therapeutics, Inc.
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
June 2, 2026
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 1, 2026
Entrada Therapeutics Reports First Quarter 2026 Financial Results
May 8, 2026
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
May 7, 2026
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
May 6, 2026
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 2, 2026
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
February 17, 2026
Entrada Therapeutics to Present at Upcoming Investor Conferences
February 4, 2026